Abstrait

Is Screening of Hepatocellular Carcinoma in Patients Without Cirrhosis Reasonable?

Viera Kissova *,Gabriel Hajas ,Adrian Kiss ,Tomas Fazekas ,Zuzana Straussova ,Jaroslav Rosenberger ,Maria Majernikova

Occurrence of hepatocellular carcinoma (HCC) in a non-cirrhotic condition of liver disease is now already well known. Non-cirrhotic condition was defined in our study as the presence of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). The rising onset of obesity, metabolic syndrome (MS) and Type 2 Diabetes Mellitus (T2DM) is associated with NAFLD or NASH. Currently only cirrhotic patients are required to be regularly (semi-annually) screened for liver neoplasma. The goal of this study was to describe the onset of HCC in patients admitted to an Internal Ward due to nonspecific symptoms of neoplasma and to identify a specific group of patients that could benefit from screening of hepatocellular carcinoma so that the disease is diagnosed in its early stages with promising prospects for successful treatment.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié